Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine PK and Dose Response for Smoking Cessation
NCT02585024Phase 1Terminated
- Sponsor
- The University of Auckland
- Start
- Feb 2016
- Primary completion
- Mar 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cytisinicline in nicotine dependence (6 arms), sponsored by The University of Auckland. Primary endpoint: Exposure (AUC) at Day 5. Started Feb 2016; status: terminated.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT02585024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585024.